Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Conclusions: PRONOUNCE is the first, international, randomized clinical trial to prospectively compare the cardiovascular safety of a GnRH antagonist and a GnRH agonist in patients with prostate cancer. The study was terminated prematurely due to smaller than planned number of participants and events and no difference in MACE at 1 year between patients assigned to degarelix or leuprolide was observed. The relative cardiovascular safety of GnRH antagonists and agonists remains unresolved. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02663908.PMID:34459214 | DOI:10.1161/CIRCULATIONAHA.121.056810

Source: Circulation - August 30, 2021 Category: Cardiology Authors: Renato D Lopes Celestia S Higano Susan F Slovin Adam J Nelson Robert Bigelow Per S S ørensen Chiara Melloni Shaun G Goodman Christopher P Evans Jan Nilsson Deepak L Bhatt Noel W Clarke Tine K Olesen Belinda T Doyle-Olsen Henriette Kristensen Lauren Arney Source Type: research